½ÃÀ庸°í¼­
»óǰÄÚµå
1545635

¼¼°èÀÇ À¯ÀüÀÚ ÆíÁý Ä¡·á ½ÃÀå

Gene Editing Therapeutics Market

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: BCC Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 111 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è À¯ÀüÀÚ ÆíÁý Ä¡·á(Gene Editing Therapy) ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä, ½ÃÀå ¿µÇâ¿äÀÎ ¹× ½ÃÀå ±âȸ ºÐ¼®, ½Å±â¼ú ¹× ±â¼ú °³¹ß µ¿Çâ, ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®, ½ÃÀå ±Ô¸ð ÃßÀÌ ¹× ¿¹Ãø, °¢Á¾ ºÎ¹®º°/Áö¿ªº° »ó¼¼ ºÐ¼®, °æÀï ±¸µµ, ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå Àü¸Á
  • Á¶»ç ¹üÀ§
  • ½ÃÀå °³¿ä

Á¦2Àå ½ÃÀå °³¿ä

  • À¯ÀüÀÚ ÆíÁý ÅøÀÇ À¯Çü
  • Meganucleases
  • Zinc Finger Nucleases
  • Transcription Activator-like Effector Nucleases
  • Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-Associated Protein
  • Gene editing Therapeutics

Á¦3Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¿ªÇÐ ÇöȲ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦

Á¦4Àå ½Å±â¼ú°ú °³¹ß

  • ±â¹Ý ÆíÁý
  • ÇÁ¶óÀÓ ÆíÁý
  • Cas-Clover¿Í Cas-FOKl
  • CRISPR °£¼·°ú CRISPR Ȱ¼ºÈ­
  • RNA ÆíÁý
  • À¯ÀüÀÚ ÆíÁý AI

Á¦5Àå ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®

  • °³¿ä
  • ÀÓ»ó½ÃÇè ºÐ¼® : ±â¼úº°
  • ÀÓ»ó½ÃÇè ºÐ¼® : Áúȯº°
  • ÆÄÀÌÇÁ¶óÀÎ ÀǾàǰ ÁöÁ¤

Á¦6Àå Æ¯Ç㠺м®

Á¦7Àå ½ÃÀå ºÐ¼®

  • Casgevy
  • ½ÃÀå °³¿ä
  • ½ÃÀå ºÐ¼®
  • Áö¿ªº° ½ÃÀå
  • ºÏ¹Ì
  • À¯·´
  • ½ÅÈï ½ÃÀå

Á¦8Àå °æÀï Á¤º¸

  • Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê
  • °æÀï ±¸µµ

Á¦9Àå À¯ÀüÀÚ ÆíÁý Ä¡·á ½ÃÀå Áö¼Ó°¡´É¼º : ȯ°æ¡¤»çȸ¡¤°Å¹ö³Í½º(ESG) °üÁ¡

  • À¯ÀüÀÚ ÆíÁý ±â¾÷ÀÇ ESG ½Çõ
  • BCCÀÇ °á·Ð

Á¦10Àå ºÎ·Ï

  • Á¶»ç ¹æ¹ý
  • ÃâÀü
  • µÎÀÚ¾î
  • ±â¾÷ °³¿ä
  • ALLOGENE THERAPEUTICS
  • BEAM THERAPEUTICS
  • CARIBOU BIOSCIENCES INC.
  • CRISPR THERAPEUTICS
  • EDITAS MEDICINE
  • INTELLIA THERAPEUTICS INC.
  • PRECISION BIOSCIENCES
  • SANGAMO THERAPEUTICS
  • VERTEX PHARMACEUTICALS INC.
  • VERVE THERAPEUTICS INC.
  • VOR BIO
LSH 24.09.10

The report provides an overview of current and future market potential of gene editing therapeutics and provides a detailed analysis of the drivers, restraints and opportunities in this market. It also include company profiles of key players, featuring detailed information regarding each company’s business segments, financials, product portfolios and recent developments. 

Report Scope:

This report highlights the current and future market potential of gene editing therapeutics and provides a detailed analysis of the drivers, restraints and opportunities in this market. It also surveys the competitive environment, including coverage of the pipeline activities adopted by market players, and it includes market projections for 2029. Also included are company profiles of key players, featuring detailed information regarding each company's business segments, financials, product portfolios and recent developments.

Report Includes:

  • 15 data tables and 42 additional tables
  • An analysis of the current and future global markets for gene editing therapeutics
  • Analyses of global market trends, with market revenue data (sales figures) for 2021-2023, estimates for 2024, and projected CAGRs through 2029
  • Estimates of the market size and revenue forecasts for the global gene editing therapeutics market, with market share analysis by region
  • Discussion of the market dynamics, opportunities, and challenges, as well as emerging technologies
  • Overview of sustainability trends and ESG developments in the industry, with emphasis on the ESG practices of leading companies, their ESG rankings, and consumer attitudes
  • Competitive intelligence, including companies' market shares, recent M&A activity, and venture funding
  • Company profiles of major players within the industry, including CRISPR Therapeutics, Vertex Pharmaceuticals, and Intellia Therapeutics

Table of Contents

Chapter 1 Executive Summary

  • Market Outlook
  • Scope of Report
  • Market Summary

Chapter 2 Market Overview

  • Introduction
  • Genome-Editing Tool Types
  • Meganucleases
  • Zinc Finger Nucleases
  • Transcription Activator-like Effector Nucleases
  • Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-Associated Protein 9
  • Gene editing Therapeutics

Chapter 3 Market Dynamics

  • Market Dynamics Snapshot
  • Market Drivers
  • Increasing Prevalence of Chronic Disease
  • Increasing Prevalence of Rare Genetic Disorders
  • Precision Medicine
  • Increasing Strategic Initiatives
  • Market Restraints
  • Stringent Regulatory Frameworks and Time-Consuming Approval Processes
  • High Cost of Treatment
  • Adverse Events and Long-Term Monitoring
  • Lack of Skilled Workforce
  • Off-Target Impact
  • Market Challenges
  • Patent Disputes
  • Governmental Policies and Regulations
  • Ethical Issues
  • Market Opportunities

Chapter 4 Emerging Technologies and Developments

  • Introduction
  • Base Editing
  • Prime Editing
  • Cas-Clover and Cas-FOKl
  • CRISPR Interference and CRISPR Activation
  • RNA Editing
  • Artificial Intelligence in Genome Editing

Chapter 5 Pipeline Analysis

  • Overview
  • Clinical Trial Analysis Based on Technology
  • Clinical Trial Analysis Based on Diseases
  • Designations for Pipeline Drugs

Chapter 6 Patent Analysis

Chapter 7 Market Analysis

  • Introduction
  • Casgevy
  • Market Overview
  • Market Analysis
  • Market by Region
  • North America
  • Europe
  • Emerging Markets

Chapter 8 Competitive Intelligence

  • Strategic Initiatives
  • Competitive Landscape

Chapter 9 Sustainability in the Gene Editing Therapeutics Market: Environmental, Social and Governance (ESG) Perspectives

  • Introduction
  • ESG Practices in the Gene Editing Companies
  • Concluding Remarks from BCC Research

Chapter 10 Appendix

  • Methodology
  • Sources
  • Acronyms
  • Company Profiles
  • ALLOGENE THERAPEUTICS
  • BEAM THERAPEUTICS
  • CARIBOU BIOSCIENCES INC.
  • CRISPR THERAPEUTICS
  • EDITAS MEDICINE
  • INTELLIA THERAPEUTICS INC.
  • PRECISION BIOSCIENCES
  • SANGAMO THERAPEUTICS
  • VERTEX PHARMACEUTICALS INC.
  • VERVE THERAPEUTICS INC.
  • VOR BIO
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦